Johnson & Johnson unit submits blood cancer drug for European review

10/31/2013 | Pharmaceutical Business Review Online

A marketing authorization application was filed by Janssen-Cilag, a Johnson & Johnson unit, with the European Medicines Agency for ibrutinib, a once-daily drug to treat two kinds of blood cancer. The drug is intended for adults with relapsed or refractory mantle cell lymphoma and for those with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic leukemia.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX